

Certificate of Analysis

Print Date: May 4th 2020

Batch No.: 1

www.tocris.com

Catalog No.: 4418

Product Name: Saquinavir mesylate

CAS Number: 149845-06-7

IUPAC Name: (2S)-N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-

1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide methanesulfonate

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{38}H_{50}N_6O_5.CH_4O_3S$

Batch Molecular Weight: 766.95 **Physical Appearance:** White solid

Storage: DMSO to 50 mM Storage: Store at +4°C

Batch Molecular Structure:

2. ANALYTICAL DATA

HPLC: Shows 100% purity

¹H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Optical Rotation: $[\alpha]_D = -48.8$ (Concentration = 0.5, Solvent = Methanol)

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 61.08 7.1 10.96 Found 61.14 7.13 10.89

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use



Product Information

Print Date: May 4th 2020

www.tocris.com

Product Name: Saquinavir mesylate Catalog No.: 4418 Batch No.: 1

CAS Number: 149845-06-7

IUPAC Name: (2S)-N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-

1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide methanesulfonate

Description:

Inhibitor of human immunodeficiency virus (HIV) protease (K_i values are <0.1 and 0.12 nM for HIV-2 and HIV-1 protease respectively). Exhibits high antiviral activity and low cytotoxicity. In silico docking models predict potential as an inhibitor of SARS-CoV-2 3CL^{pro}.

Physical and Chemical Properties:

Batch Molecular Formula: C₃₈H₅₀N₆O₅.CH₄O₃S

Batch Molecular Weight: 766.95 Physical Appearance: White solid

Minimum Purity: ≥99%

Batch Molecular Structure:

Storage: Store at +4°C

Solubility & Usage Info:

DMSO to 50 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Hall and Hai-Feng et al (2020) A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med.Infect.Dis.. PMID: 32294562.

Kaldor et al (1995) Isophthalic acid derivatives: amino acid surrogates for the inhibition of HIV-1 protease. Bioorg.Med.Chem.Lett. 5 721.

Krausslich *et al* (1992) Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. J.Virol. *66* 567. PMID: 1727499.

Tucker *et al* (1992) A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity. J.Med.Chem. *35* 2525. PMID: 1635054.

Roberts et al (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248 358. PMID: 2183354.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use